Design of Targeted Metal Chelation Therapeutics Nanocapsules as Colloidal Carriers and Blood-Brain Barrier (BBB) Translocation to Targeted Deliver Anti-Cancer Nano Drugs into the Human Brain to Treat Alzheimer's Disease under Synchrotron Radiation

HDS (Hydrodesulphurization Reaction) is a catalytic chemical process widely used to design of targeted metal chelation therapeutics nano-capsules as colloidal carriers and Blood–Brain Barrier (BBB) translocation to targeted deliver anti–cancer nano drugs into the human brain to treat Alzheimer's disease under synchrotron radiation[1-23]. The purpose of removing the sulphur is to design of targeted metal chelation therapeutics nano-capsules as colloidal carriers and Blood–Brain Barrier (BBB) translocation to targeted deliver anti–cancer nano drugs into the human brain to treat Alzheimer's disease under synchrotron radiation[24-44]. Another important reason is that sulphur, even in extremely low concentrations, poisons the novel metal catalysts (Platinum and Rhenium) in the catalytic reforming units that are subsequently used to upgrade the octane rating of the naphtha streams[45-73]. In this short communication, paclitaxel, camptothecin, doxorubicin, cisplatin and curcumin are most used anti–cancer nano drugs, which are tested for nano-medicinal and pharmaceutical applications. The anti–cancer nano drugs are mostly encapsulated into the liposomes or micelles or conjugated with Polyethylene Glycol (PEG) were coated with WO3 nano-particles to design of targeted metal chelation therapeutics nano-capsules as colloidal carriers and Blood–Brain Barrier (BBB) translocation to targeted deliver anti–cancer nano drugs into the human brain to treat Alzheimer's disease under synchrotron radiation.